Agenus (NASDAQ:AGEN) Price Target Lowered to $7.00 at HC Wainwright

Agenus (NASDAQ:AGEN) had its price objective lowered by analysts at HC Wainwright from $8.00 to $7.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 116.05% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. Jefferies Financial Group reaffirmed a “hold” rating and set a $7.00 price target (up previously from $3.00) on shares of Agenus in a research note on Friday, July 19th. Robert W. Baird cut Agenus from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $35.00 to $8.00 in a report on Friday, July 19th. Baird R W lowered Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. StockNews.com downgraded shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Finally, William Blair cut shares of Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Agenus presently has an average rating of “Hold” and an average price target of $10.00.

Agenus Price Performance

Shares of NASDAQ AGEN traded down $0.66 during trading on Tuesday, hitting $3.24. 672,054 shares of the company were exchanged, compared to its average volume of 639,793. The firm’s fifty day moving average price is $4.86 and its 200 day moving average price is $8.91. The company has a market cap of $69.89 million, a price-to-earnings ratio of -0.29 and a beta of 1.39. Agenus has a 1 year low of $3.20 and a 1 year high of $19.69.

Institutional Trading of Agenus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after acquiring an additional 4,134,232 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Agenus by 1,959.9% in the 1st quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 720,629 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 123,058 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Agenus by 81.3% during the 1st quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after buying an additional 84,477 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new position in shares of Agenus in the 2nd quarter worth $1,921,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.